中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

42 records (took 0.026 seconds)

    NOVEL RECOMBINANT PLASMID PSG1-12
    11.
    发明专利
    NOVEL RECOMBINANT PLASMID PSG1-12 失效

    公开(公告)号：JPH02138981A

    公开(公告)日：1990-05-28

    申请号：JP29338988

    申请日：1988-11-19

    Applicant: AGENCY IND SCIENCE TECHN

    Inventor： IWAKURA MASAHIRO ,  OHASHI SHINICHI ,  TANAKA YOSHIO

    IPC: C12N15/09 ,  C07K14/00 ,  C07K14/575 ,  C07K14/60 ,  C07K19/00 ,  C12N1/21 ,  C12N15/18 ,  C12N15/62 ,  C12N15/70 ,  C12P21/02 ,  C12R1/19

    Abstract: PURPOSE:To mass-produce a GRF1-29 derivative by forming a recombinant plasmid pSG1-12 having a DNA sequence coding a peptide fragment of GRF with a fused protein of dihydrofolate reductase. CONSTITUTION:A recombinant plasmid pSG1-12, stably replicative in Escherichia coli, capable of imparting tolerance to trimethoprim and ampicillin to Escherichia coli which is a host, coding a fused protein of a peptide fragment of a growth hormone releasing factor having a specific amino acid sequence and a dihydrofolate reductase and forming a recombinant plasmid and having a specific DNA sequence is formed. The recombinant plasmid encodes DHFR- GRFM and Escherichia coli having the pSG1-12 is capable of accumulating and producing the DHFR-GRFM in a large amount.

    ANGIOTENSIN I
    13.
    发明专利
    ANGIOTENSIN I 失效

    公开(公告)号：JPH01252287A

    公开(公告)日：1989-10-06

    申请号：JP7967888

    申请日：1988-03-31

    Applicant: AGENCY IND SCIENCE TECHN

    Inventor： IWAKURA MASAHIRO ,  OHASHI SHINICHI ,  SAKAI TSUKASA ,  TANAKA YOSHIO

    IPC: C12N15/09 ,  C07K1/14 ,  C07K1/22 ,  C07K7/14 ,  C07K14/00 ,  C07K19/00 ,  C12N1/20 ,  C12N1/21 ,  C12N9/06 ,  C12P21/02 ,  C12R1/19

    Abstract: PURPOSE:To obtain a large amount of dihydrofolic acid reductase-angiotensin fused protein, by manifesting a fused gene in which an angiotensin I gene is included in a recombined plasmid pLEK1 with a colon bacillus. CONSTITUTION:A newly recombined plasmid pANG1-23, which is replicated in stable with a colon bacillus, imparting resistance to trimethoprim and resistance to ampicillin to a colon bacillus as a host, having a size of 4222 basic pairs and having a replaced structure with a conformation of 28 basic pairs containing a conformation coding leucine enkephaline between BamHI site and MluI site in pLEK1 to a chemically synthesized DNA of 43 basic pairs containing a conformation coding angiotensin I, is produced. A colon bacillus introduced of pANG1-23 produces a large amount of dihydrofolic acid reductase- angiotensin fused protein.

    PRODUCTION OF DIVINYL ETHER-MALEIC ANHYDRIDE COPOLYMER HAVING PHARMACOLOGICAL ACTIVITY
    15.
    发明专利
    PRODUCTION OF DIVINYL ETHER-MALEIC ANHYDRIDE COPOLYMER HAVING PHARMACOLOGICAL ACTIVITY 失效

    公开(公告)号：JPS6322803A

    公开(公告)日：1988-01-30

    申请号：JP31283586

    申请日：1986-12-26

    Applicant: AGENCY IND SCIENCE TECHN

    Inventor： HIRANO TAKASHI ,  OHASHI SHINICHI ,  MORIMOTO SATOSHI ,  SHIRAKI MASARU ,  TSUDA KEISHIRO ,  KOBAYASHI TOMOO ,  TSUKAGOSHI SHIGERU

    IPC: A61K31/765 ,  A61K45/00 ,  A61K47/48 ,  A61P35/00 ,  C08F8/30

    Abstract: PURPOSE:To obtain a copolymer having excellent slow-releasing property of a carcinostatic substance, low toxicity and improved carcinostatic effect, by reacting a carcinostatic substance to a divinyl ether-maleic anhydride copolymer and hydrolyzing the reaction product. CONSTITUTION:A divinyl ether-maleic anhydride copolymer of formula I (n is a value corresponding to the copolymer molecular weight of 2,000-15,000) is made to react with a carcinostatic substance having hydroxyl group or amino group (e.g. 5-fluorouridine, 1-beta-D-arabinofuranosylcytosine) in the presence of an organic solvent (e.g. N-methylpyrrolidone) at a rate to give a content of usually 5-40wt%. The reaction product is hydrolyzed and optionally converted to a salt to obtain the objective copolymer of formula II (R is residue obtained by removing one H atom from the hydroxyl group or amino group of the above carcinostatic substance). EFFECT:The carcinostatic activity is promoted by the synergistic effect with the carcinostatic activity of the copolymer.

    PRODUCTION OF IMMOBILIZED ENZYME
    16.
    发明专利
    PRODUCTION OF IMMOBILIZED ENZYME 失效

    公开(公告)号：JPH0833485A

    公开(公告)日：1996-02-06

    申请号：JP32954091

    申请日：1991-11-18

    Applicant: AGENCY IND SCIENCE TECHN

    Inventor： IWAKURA MASAHIRO ,  KOKUBU TOMOKUNI ,  OHASHI SHINICHI

    IPC: C12N11/00 ,  C12N9/06

    Abstract: PURPOSE:To obtain a highly active immobilized enzyme for bioreactor, etc., in high efficiency by introducing an amino acid sequence having a cysteine residue at the terminal to the carboxy-terminal of an enzyme protein and immobilizing the modified protein to a carrier through an SH group. CONSTITUTION:This immobilized enzyme having high uniformity and activity and useful as an element of a bioreactor, etc., is produced by constructing an expression vector coding a modified enzyme protein obtained by introducing a short amino acid sequence to the carboxy terminal of an enzyme protein (e.g. dihydrofolate reductase) to form cysteine residue on the carboxy terminal of the protein, introducing the expression vector into a host cell, culturing the transformed cell to effect the expression of the gene and obtain a modified enzyme protein having an amino acid sequence composed of several number of amino acid residues having a cysteine residue terminal on the carboxy terminal of the enzyme protein and bonding the modified protein to an immobilization carrier through a mercapto group of the cysteine residue at the carboxy terminal.

    17.
    发明专利
    失效

    公开(公告)号：JPH05339295A

    公开(公告)日：1993-12-21

    申请号：JP34867791

    申请日：1991-12-05

    Applicant: AGENCY IND SCIENCE TECHN

    Inventor： IWAKURA MASAHIRO ,  KOKUBU TOMOKUNI ,  OHASHI SHINICHI

    IPC: C07K16/00 ,  C07K14/00 ,  C07K19/00 ,  C12N15/09 ,  C12N15/62 ,  C12P21/02 ,  C12R1/19 ,  C07K15/14

    Abstract: PURPOSE:To produce an antibody by bonding the objective peptide to the carboxyl terminal of dihydrofolic acid reductase(DHFR) and using the produced fused protein as an immunizing antibody. CONSTITUTION:The objective process for the preparation of an antibody against a peptide is composed of a process for producing a DHFR fused protein having the objective peptide on the carboxyl terminal side by genetic engineering technique, a process for separating the objective fused protein from the host microorganism and purifying the protein and a process for immunizing an animal using the objective highly purified fused protein.

    18.
    发明专利
    失效

    公开(公告)号：JPH05310819A

    公开(公告)日：1993-11-22

    申请号：JP10592192

    申请日：1992-03-31

    Applicant: AGENCY IND SCIENCE TECHN

    Inventor： HIRANO TAKASHI ,  KOKUBU TOMOKUNI ,  OHASHI SHINICHI

    IPC: A61K31/70 ,  A61K31/765 ,  A61P35/00 ,  A61P43/00 ,  C08F8/32 ,  C08F8/42 ,  C08F8/44 ,  C08F16/32 ,  C08F20/02 ,  C08F216/12 ,  C08F222/06

    Abstract: PURPOSE:To obtain an arabinofuranosylcytosine having low toxicity and an excellent carcinostatic effect by incorporating an arabinofuranosylcytosine residue into a divinyl ether/maleic anhydride copolymer through the medium of a specific group. CONSTITUTION:A divinyl ether/maleic anhydride copolymer represented by formula II (wherein m is an integer of 10-500) is reacted in an inert organic solvent with an amino acid represented by the formula H2N-(CH2)n-COOH (wherein n is an integer of 1-11) and then with arabinofuranosylcytosine. According to need, the reaction product is converted into a salt form. The obtained derivative contains 10-500 repeating units represented by formula I (wherein R is H or an arabinofuranosylcytosine residue and n is an integer of 1 to 11), at least 10mol% of the units containing an arabinofuranosylcytosine residue as R.

    19.
    发明专利
    失效

    公开(公告)号：JPH05308992A

    公开(公告)日：1993-11-22

    申请号：JP10592092

    申请日：1992-03-31

    Applicant: AGENCY IND SCIENCE TECHN

    Inventor： KOKUBU TOMOKUNI ,  IWAKURA MASAHIRO ,  OHASHI SHINICHI

    IPC: A61K39/395 ,  C12N5/10 ,  C12N5/20 ,  C12N15/02 ,  C12N15/06 ,  C12P21/08 ,  C12R1/91 ,  G01N33/53 ,  G01N33/577

    Abstract: PURPOSE:To obtain monoclonal antibodies against leucine enkephalin. CONSTITUTION:The monoclonal antibodies RIPT36 and RIPT74 against leucine enkephalin(LEK) and a hybridoma cell capable of producing the antibodies. Uniform anti-LEK monoclonal antibodies can always be obtained in a required sufficient amount and the resultant antibodies can be used to extremely specifically analyze the LEK present in a living body specimen, etc., according to various methods and applied to the diagnostic medical field, etc.

Patent Agency Ranking